Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y.

Cancer Res. 2012 Nov 1;72(21):5588-99. doi: 10.1158/0008-5472.CAN-12-2753.

2.

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.

Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y.

Mol Cancer Ther. 2014 Feb;13(2):433-43. doi: 10.1158/1535-7163.MCT-13-0803. Epub 2013 Dec 19.

3.

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.

Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino EL, Panchal SC, Wilsbacher JL, Gao W, Olson AM, Stolarik DF, Osterling DJ, Johnson EF, Maag D.

Mol Cancer Res. 2015 Nov;13(11):1465-77. doi: 10.1158/1541-7786.MCR-15-0191-T. Epub 2015 Jul 27.

4.

Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.

Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y.

J Pharmacol Exp Ther. 2014 Jun;349(3):408-16. doi: 10.1124/jpet.113.210146. Epub 2014 Mar 20.

5.

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.

Postel-Vinay S, Bajrami I, Friboulet L, Elliott R, Fontebasso Y, Dorvault N, Olaussen KA, André F, Soria JC, Lord CJ, Ashworth A.

Oncogene. 2013 Nov 21;32(47):5377-87. doi: 10.1038/onc.2013.311. Epub 2013 Aug 12.

PMID:
23934192
6.

Trapping Poly(ADP-Ribose) Polymerase.

Shen Y, Aoyagi-Scharber M, Wang B.

J Pharmacol Exp Ther. 2015 Jun;353(3):446-57. doi: 10.1124/jpet.114.222448. Epub 2015 Mar 10.

7.

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.

Thorsell AG, Ekblad T, Karlberg T, Löw M, Pinto AF, Trésaugues L, Moche M, Cohen MS, Schüler H.

J Med Chem. 2017 Feb 23;60(4):1262-1271. doi: 10.1021/acs.jmedchem.6b00990. Epub 2016 Dec 21.

PMID:
28001384
8.

Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.

Ghosh R, Roy S, Kamyab J, Danzter F, Franco S.

DNA Repair (Amst). 2016 Sep;45:56-62. doi: 10.1016/j.dnarep.2016.06.001. Epub 2016 Jun 16.

PMID:
27373144
9.

[Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].

Wang W, Duan B, Zeng L.

Zhongguo Fei Ai Za Zhi. 2016 Jan;19(1):16-23. doi: 10.3779/j.issn.1009-3419.2016.01.02. Chinese.

10.

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.

Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL.

Breast Cancer Res Treat. 2012 Jul;134(2):649-59. doi: 10.1007/s10549-012-2106-5. Epub 2012 Jun 8.

11.

Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.

Chornenkyy Y, Agnihotri S, Yu M, Buczkowicz P, Rakopoulos P, Golbourn B, Garzia L, Siddaway R, Leung S, Rutka JT, Taylor MD, Dirks PB, Hawkins C.

Mol Cancer Ther. 2015 Nov;14(11):2560-8. doi: 10.1158/1535-7163.MCT-15-0282. Epub 2015 Sep 8.

12.

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.

Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR 4th, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC.

Nat Med. 2016 Feb;22(2):194-201. doi: 10.1038/nm.4032. Epub 2016 Jan 18.

13.

Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.

Pan MR, Hsieh HJ, Dai H, Hung WC, Li K, Peng G, Lin SY.

J Biol Chem. 2012 Feb 24;287(9):6764-72. doi: 10.1074/jbc.M111.287037. Epub 2012 Jan 4.

14.

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.

Gill SJ, Travers J, Pshenichnaya I, Kogera FA, Barthorpe S, Mironenko T, Richardson L, Benes CH, Stratton MR, McDermott U, Jackson SP, Garnett MJ.

PLoS One. 2015 Oct 27;10(10):e0140988. doi: 10.1371/journal.pone.0140988. eCollection 2015.

15.

Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.

Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, Issaeva N, Sleeth K, Sharma RA, Helleday T.

Cancer Res. 2010 Jul 1;70(13):5389-98. doi: 10.1158/0008-5472.CAN-09-4716. Epub 2010 Jun 15. Erratum in: Cancer Res. 2011 Apr 1;71(7):2803.

16.

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.

Frankum J, Moudry P, Brough R, Hodny Z, Ashworth A, Bartek J, Lord CJ.

Oncotarget. 2015 May 10;6(13):10746-58.

17.

[Cancer therapy by PARP inhibitors].

Seimiya H.

Nihon Rinsho. 2015 Aug;73(8):1330-5. Review. Japanese.

PMID:
26281686
18.

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH.

Clin Cancer Res. 2012 Mar 15;18(6):1655-62. doi: 10.1158/1078-0432.CCR-11-2890. Epub 2012 Jan 30.

19.

[PARP inhibitors--theoretical basis and clinical application].

Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P.

Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21. Review. Polish.

20.

Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.

Sun Y, Gallacchi D, Zhang EY, Reynolds SB, Robinson L, Malinowska IA, Chiou TT, Pereira AM, Li C, Kwiatkowski DJ, Lee PS, Yu JJ.

Am J Respir Cell Mol Biol. 2014 Dec;51(6):738-49. doi: 10.1165/rcmb.2014-0033OC.

Supplemental Content

Support Center